VRTX

Vertex Pharmaceuticals (VRTX)

Vertex Pharmaceuticals Inc

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:VRTX

<< 前へ 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2023/12/07	06 : 03	Edgar (US Regulatory)	Form 3 - Initial statement of beneficial ownership of securities	NASDAQ:VRTX	Vertex Pharmaceuticals Inc
2023/12/06	06 : 14	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:VRTX	Vertex Pharmaceuticals Inc
2023/12/06	06 : 01	Business Wire	Vertex Appoints Nancy Thornberry to its Board of Directors	NASDAQ:VRTX	Vertex Pharmaceuticals Inc
2023/11/30	04 : 55	Dow Jones News	Vertex Pharmaceuticals' Kalydeco Gets Expanded Use Authorization from Health Canada	NASDAQ:VRTX	Vertex Pharmaceuticals Inc
2023/11/30	04 : 00	PR Newswire (Canada)	Santé Canada autorise la mise sur le marché de KALYDECO(MD) (ivacaftor) pour les enfants admissibles atteints de fibrose kystique âgés de 2 mois et plus	NASDAQ:VRTX	Vertex Pharmaceuticals Inc
2023/11/30	03 : 59	PR Newswire (Canada)	Health Canada Grants Market Authorization for KALYDECO® (ivacaftor) for Eligible Children With Cystic Fibrosis Ages 2 Months and Older	NASDAQ:VRTX	Vertex Pharmaceuticals Inc
2023/11/25	00 : 06	Dow Jones News	Vertex Pharmaceuticals Gets Regulatory OK to Extend Use to More Patients in Europe	NASDAQ:VRTX	Vertex Pharmaceuticals Inc
2023/11/24	23 : 13	Business Wire	Vertex Announces European Medicines Agency Validation for Marketing Authorization Application Extension for KAFTRIO® in Combination With Ivacaftor to Include People With Cystic Fibrosis and Responsive Rare Mutations	NASDAQ:VRTX	Vertex Pharmaceuticals Inc
2023/11/23	23 : 54	Dow Jones News	Vertex Pharmaceuticals Cystic Fibrosis Treatment Approved for Young Children in EU	NASDAQ:VRTX	Vertex Pharmaceuticals Inc
2023/11/23	23 : 05	Business Wire	European Commission Approves KAFTRIO® in Combination With Ivacaftor for the Treatment of Children With Cystic Fibrosis Ages 2 Through 5	NASDAQ:VRTX	Vertex Pharmaceuticals Inc
2023/11/22	06 : 07	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:VRTX	Vertex Pharmaceuticals Inc
2023/11/21	01 : 54	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:VRTX	Vertex Pharmaceuticals Inc
2023/11/18	06 : 16	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:VRTX	Vertex Pharmaceuticals Inc
2023/11/18	06 : 11	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:VRTX	Vertex Pharmaceuticals Inc
2023/11/17	06 : 15	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:VRTX	Vertex Pharmaceuticals Inc
2023/11/16	15 : 45	Business Wire	Vertex and CRISPR Therapeutics Announce Authorization of the First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), by the United Kingdom MHRA for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia	NASDAQ:VRTX	Vertex Pharmaceuticals Inc
2023/11/16	06 : 16	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:VRTX	Vertex Pharmaceuticals Inc
2023/11/16	04 : 32	Dow Jones News	Vertex Pharmaceuticals Worst Performer in the S&P 500 and the Nasdaq 100 So Far Today -- Data Talk	NASDAQ:VRTX	Vertex Pharmaceuticals Inc
2023/11/16	00 : 29	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:VRTX	Vertex Pharmaceuticals Inc
2023/11/16	00 : 26	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:VRTX	Vertex Pharmaceuticals Inc
2023/11/15	01 : 59	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:VRTX	Vertex Pharmaceuticals Inc
2023/11/14	05 : 51	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:VRTX	Vertex Pharmaceuticals Inc
2023/11/09	06 : 11	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:VRTX	Vertex Pharmaceuticals Inc
2023/11/08	06 : 16	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:VRTX	Vertex Pharmaceuticals Inc
2023/11/07	21 : 10	IH Market News	Tuesday’s Wall Street Highlights: WeWork, UBS, Sanofi, Alteryx, Intel, and more.	NASDAQ:VRTX	Vertex Pharmaceuticals Inc
2023/11/07	06 : 46	Dow Jones News	Vertex Pharmaceuticals 3Q Profit Rises on Continued Sales Strength	NASDAQ:VRTX	Vertex Pharmaceuticals Inc
2023/11/07	06 : 05	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:VRTX	Vertex Pharmaceuticals Inc
2023/11/07	06 : 01	Business Wire	Vertex Reports Third Quarter 2023 Financial Results	NASDAQ:VRTX	Vertex Pharmaceuticals Inc
2023/11/07	01 : 50	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:VRTX	Vertex Pharmaceuticals Inc
2023/11/03	05 : 07	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:VRTX	Vertex Pharmaceuticals Inc